Pfizer and OPKO’s Ngenla (somatrogon) Receives EC’s Marketing Authorization for the Treatment of Pediatric Growth Hormone Deficiency
Shots:
- The marketing authorization was based on the P-III study to evaluate the safety & efficacy of Ngenla (qw) vs Genotropin (qd) in a ratio (1:1) in 224 prepubertal, treatment-naïve patients aged ≥3yrs. with GHD at ~20 countries
- The study met its 1EPs of non-inferiority as measured by annual height velocity @12mos., was well tolerated & had a safety profile, 95% of patients switched into the open-label extension study & received the treatment, improved the mean overall life interference total score @12wks.
- Ngenla is approved for pediatric GHD in Canada, Australia & Japan while the marketing authorization is valid in all EU Member States, Iceland, Norway & Liechtenstein
Ref: Pfizer | Image: Pfizer
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com